Institute of Clinical Chemistry and Clinical Pharmacology, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Pharmacy of the University Hospital Bonn, Bonn, Germany.
Clin Drug Investig. 2023 Jul;43(7):475-502. doi: 10.1007/s40261-023-01289-0. Epub 2023 Jul 18.
The presence of liver cirrhosis affects the selection and dosing of drugs metabolised by the liver as doses have to be adjusted to the remaining liver function. This is a major challenge in clinical practice as specific guidelines are lacking. The aim of this study was to identify drugs for which recommendations on selection and dose adjustments for patients with cirrhosis exist by assessing the literature according to certain quality standards, paying particular attention to the suitability of these recommendations for clinical practice.
A systematic literature review included peer-reviewed publications that were published by October 2020 in PubMed in the English language and aimed to generate recommendations on dose adjustment in patients with liver cirrhosis. Subsequently, the identified publications were checked for reporting quality against the relevant reporting guidelines and the Oxford Centre for Evidence-Based Medicine Levels of Evidence. Finally, all specific dose recommendations were extracted, compared with the specifications of the Summaries of Product Characteristics and mapped according to the Anatomical Therapeutic Chemical/Defined Daily Dose Index.
Eighteen publications covering a total of 1145 dose recommendations for 481 active substances were identified. There were 706 recommendations for 316 substances sufficiently specific for application in clinical practice. For 22 active substances, the specific recommendations were consistent across multiple publications, of which only six were also consistent with the respective Summaries of Product Characteristics.
As the majority of dose recommendations were not sufficiently specific or even contradictory, there is an urgent need for the definition of standard parameters for a uniform assessment of drugs in liver cirrhosis. In addition, dose recommendations should be aligned by suitable methods.
肝硬化的存在会影响经肝脏代谢的药物的选择和剂量,因为需要根据剩余肝功能调整剂量。这在临床实践中是一个重大挑战,因为缺乏特定的指南。本研究的目的是通过评估文献,根据某些质量标准确定存在针对肝硬化患者的药物选择和剂量调整建议的药物,特别关注这些建议对临床实践的适用性。
一项系统的文献综述包括截至 2020 年 10 月在 PubMed 上以英文发表的同行评审出版物,旨在为肝硬化患者的剂量调整生成建议。随后,根据相关报告指南和牛津循证医学中心证据水平对确定的出版物进行报告质量检查。最后,提取所有特定的剂量建议,与产品特性摘要进行比较,并根据解剖治疗化学/规定日剂量索引进行映射。
共确定了 18 篇涵盖总共 1145 种针对 481 种活性物质的剂量建议的出版物。有 706 种针对 316 种物质的建议在临床实践中具有足够的特异性。对于 22 种活性物质,多个出版物中的具体建议是一致的,其中只有 6 种与各自的产品特性摘要一致。
由于大多数剂量建议不够具体甚至相互矛盾,因此迫切需要定义标准参数,以统一评估肝硬化中的药物。此外,应通过合适的方法调整剂量建议。